Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE PRIME STUDY, ONE OF THE LARGEST STUDIES ON PRETERM BIRTH, HAS BEEN ACCEPTED FOR PUBLICATION BY A MEDICAL JOURNAL FOLLOWING ABSTRACT PRESENTATION EARLIER THIS YEAR SALT LAKE CITY , NOV. 24, 2025 /PRNEWSWIRE/ -- SERA PROGNOSTICS, INC. , THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED THAT THE FINDINGS OF THE PREMATURITY RISK ASSESSMENT COMBINED WITH CLINICAL INTERVENTIONS FOR IMPROVED NEONATAL OUTCOMES (PRIME) STUDY WERE ACCEPTED FOR PUBLICATION IN A PEER-REVIEWED JOURNAL. THE PRIME STUDY'S ABSTRACT DATA WAS SELECTED AS A LATE-BREAKING ABSTRACT FOR PODIUM PRESENTATION EARLIER THIS YEAR AT THE SOCIETY FOR MATERNAL-FETAL MEDICINE'S (SMFM) ANNUAL MEETING.

SERA ANNOUNCES PUBLICATION ACCEPTANCE FOR PRIME STUDY

SALT LAKE CITY , NOV. 13, 2025 /PRNEWSWIRE/ --SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025 ENDED SEPTEMBER 30, 2025. THIRD QUARTER AND RECENT HIGHLIGHTS: MEANINGFUL PROGRESS ON PAYER INITIATIVES, INCLUDING AN INAUGURAL PILOT IN NEVADA ACTIVELY ENROLLING MEDICAID PATIENTS, WHILE ENGAGING WITH MULTIPLE PAYERS ACROSS THIRTEEN STATES, COLLECTIVELY REPRESENTING A SIGNIFICANT OPPORTUNITY.

SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

SALT LAKE CITY , OCT. 30, 2025 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED IT WILL REPORT THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON THURSDAY NOVEMBER 13, 2025, AFTER THE CLOSE OF THE MARKET. THE COMPANY WILL HOST A CORRESPONDING CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS OPERATIONAL HIGHLIGHTS, FINANCIAL RESULTS AND KEY TOPICS AT5:00 P.M.

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025

SALT LAKE CITY , OCT. 1, 2025 /PRNEWSWIRE/ --SERA PROGNOSTICS INC., THE PREGNANCY COMPANY(NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER TESTING TO HELP DELIVER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCEDTHE APPOINTMENT OF TIFFANY INGLIS, MD, FACOG, AS CHIEF MEDICAL OFFICER. WITH EXTENSIVE CLINICAL LEADERSHIP EXPERTISE, DR. INGLIS WILL LEAD SERA'S CLINICAL OPERATIONS TO ESTABLISH THE COMPANY AS A LEADER IN WOMEN'S HEALTH DIAGNOSTICS TO IMPROVE THE HEALTH OF PREGNANT WOMEN AND NEWBORNS.

SERA PROGNOSTICS NAMES DR. TIFFANY INGLIS CHIEF MEDICAL OFFICER

SALT LAKE CITY , AUG. 28, 2025 /PRNEWSWIRE/ --SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE ON FRIDAY, SEPTEMBER 5, 2025 AT 7:00 A.M.

SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

SALT LAKE CITY , AUG. 6, 2025 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 ENDED JUNE 30, 2025. SECOND QUARTER AND RECENT HIGHLIGHTS: ONGOING PROGRESS IN ENGAGING MEDICAID PLANS IN TARGETED STATES WITH PRIOR PRETRM CLINICAL STUDY EXPERIENCE.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

SALT LAKE CITY , JULY 29, 2025 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED THAT IT WILL REPORT SECOND QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON WEDNESDAY, AUGUST 6, 2025, AFTER THE CLOSE OF THE MARKET. THE COMPANY WILL HOST A CORRESPONDING CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS OPERATIONAL HIGHLIGHTS, FINANCIAL RESULTS AND KEY TOPICS AT 5:00 P.M.

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON AUGUST 6, 2025

SALT LAKE CITY , MAY 29, 2025 /PRNEWSWIRE/ -- SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED THAT MEMBERS OF THE SERA TEAM WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: WILLIAM BLAIR 45TH ANNUAL GROWTH STOCK CONFERENCE DATE: JUNE 3  5, 20251X1 MEETINGS ONLYDOUGFISHER, M.D., STRATEGIC ADVISOR TO SERA AND FORMER CHIEF BUSINESS OFFICER, WILL PARTICIPATE IN MEETINGS ON WEDNESDAY, JUNE 4, 2025.

SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SALT LAKE CITY, MAY 14, 2025 /PRNEWSWIRE/ --SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT AT THE RBC GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, MAY 21, 2025, FROM 9:30  9:55 A.M. ET. ZHENYA LINDGARDT, PRESIDENT AND CEO, WILL PARTICIPATE IN A FIRESIDE CHAT AND PROVIDE A COMPANY UPDATE AND DISCUSS THE COMPANY'S LATEST ACHIEVEMENTS.

SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE

INDUSTRY VETERAN TO SPEARHEAD COMMERCIAL EXPANSION, DRIVING INNOVATION AND GROWTH AT THE COMPANY SALT LAKE CITY , MAY 8, 2025 /PRNEWSWIRE/ --SERA PROGNOSTICS INC., THE PREGNANCY COMPANY (NASDAQ: SERA), FOCUSED ON IMPROVING MATERNAL AND NEONATAL HEALTH BY PROVIDING INNOVATIVE PREGNANCY BIOMARKER INFORMATION TO DOCTORS AND PATIENTS, TODAY ANNOUNCED THE APPOINTMENT OF LEE ANDERSON AS CHIEF COMMERCIAL OFFICER. BRINGING MORE THAN 30 YEARS OF CROSS-FUNCTIONAL LEADERSHIP EXPERIENCE IN SALES, MARKETING, CUSTOMER SERVICE, STRATEGIC ACCOUNTS, AND TRAINING, MR.

Sera Prognostics, Inc.

SERA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Sera Prognostics, Inc.

SERA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SERA